Xintela

Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.

First quarter 2023 for the group
Income amounted to TSEK 0 (0).
Loss before and tax totalled TSEK 15,843 (loss: 16,383).
Loss per share* was SEK 0.05 (loss: 0.18).
 
First quarter 2023 for the parent company
Income amounted to TSEK 0 (0).
Loss before and after tax totalled TSEK 10,403 (loss: 11,042).
Loss per share* was SEK 0.03 (loss: 0.12).
At March 31, 2023, the equity/assets ratio** was 45 % (0).
 
Significant events in the first quarter of 2023
» Xintela completes dosing of XSTEM second dose level in knee osteoarthritis clinical study. (March 3, 2023)

Significant events after the end of the period
» Xintela has started last dose level of XSTEM in knee osteoarthritis clinical study. (April 13, 2023)
» Communiqué from the Annual General Meeting of Xintela AB (publ). (May 12, 2023)
» Xintela is carrying out a Rights issue of units of approximately SEK 123 million. (May 24, 2023)
 
The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.